Multidrug-resistant enterococci: the dawn of a new era in resistant pathogens.
Resistant enterococci, especially vancomycin-resistant enterococci, have rapidly become an important nosocomial pathogen. They are increasingly prevalent among hospitalized patients, patients with serious chronic illnesses, and immunosuppressed patients. Risk factors identified include previous antibiotics, exposure to contaminated equipment, and close proximity to infected patients. Treatment of multidrug-resistant pathogens has become increasingly difficult, with increased morbidity and mortality in these patients. Strict infection control measures remain the mainstay in the management of these infections.
Texas Oncology PA and Texas Tech University Medical Center, El Paso 79915, USA.
S J
SJ
Antony
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy; D018432:Drug Resistance, Multiple; D016983:Enterococcus / Q000187:drug effects*; D016905:Gram-Negative Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy; D006801:Humans; D008826:Microbial Sensitivity Tests; D012307:Risk Factors
D000900:Anti-Bacterial Agents